These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Update from the Laboratory: Clinical Identification and Susceptibility Testing of Fungi and Trends in Antifungal Resistance. Albataineh MT; Sutton DA; Fothergill AW; Wiederhold NP Infect Dis Clin North Am; 2016 Mar; 30(1):13-35. PubMed ID: 26739605 [TBL] [Abstract][Full Text] [Related]
23. Antifungal drug resistance: evolution, mechanisms and impact. Revie NM; Iyer KR; Robbins N; Cowen LE Curr Opin Microbiol; 2018 Oct; 45():70-76. PubMed ID: 29547801 [TBL] [Abstract][Full Text] [Related]
24. Invasive fungal infections: past achievements and challenges ahead. Arendrup MC Clin Microbiol Infect; 2009 Jul; 15(7):599-601. PubMed ID: 19673970 [No Abstract] [Full Text] [Related]
25. Pharmacology and clinical use of voriconazole. Thompson GR; Lewis JS Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):83-94. PubMed ID: 19947892 [TBL] [Abstract][Full Text] [Related]
26. Heteroresistance and fungi. Ferreira GF; Santos DA Mycoses; 2017 Sep; 60(9):562-568. PubMed ID: 28660647 [TBL] [Abstract][Full Text] [Related]
27. [Drug resistance in the treatment of invasive fungal infections]. Nordøy I; Gaustad P Tidsskr Nor Laegeforen; 2008 Nov; 128(22):2607-11. PubMed ID: 19023376 [TBL] [Abstract][Full Text] [Related]
28. Clinical pharmacology of antifungal agents to overcome drug resistance in pediatric patients. Stergiopoulou T; Walsh TJ Expert Opin Pharmacother; 2015 Feb; 16(2):213-26. PubMed ID: 25579070 [TBL] [Abstract][Full Text] [Related]
30. Systemic Antifungal Agents: Current Status and Projected Future Developments. Seyedmousavi S; Rafati H; Ilkit M; Tolooe A; Hedayati MT; Verweij P Methods Mol Biol; 2017; 1508():107-139. PubMed ID: 27837500 [TBL] [Abstract][Full Text] [Related]
31. The value of amphotericin B in the treatment of invasive fungal infections. Klepser M J Crit Care; 2011 Apr; 26(2):225.e1-10. PubMed ID: 20951541 [TBL] [Abstract][Full Text] [Related]
32. Mitigation of human-pathogenic fungi that exhibit resistance to medical agents: can clinical antifungal stewardship help? Hull CM; Purdy NJ; Moody SC Future Microbiol; 2014; 9(3):307-25. PubMed ID: 24762306 [TBL] [Abstract][Full Text] [Related]
33. Epidemiology of antifungal susceptibility: Review of literature. Hadrich I; Ayadi A J Mycol Med; 2018 Sep; 28(3):574-584. PubMed ID: 29773435 [TBL] [Abstract][Full Text] [Related]
34. Targeting Stress Response Pathways with Alternative Strategies as a Novel Antifungal Approach. Ruhil S; Kumar V; Balhara M; Malik M; Chhillar AK Mini Rev Med Chem; 2021; 21(16):2337-2346. PubMed ID: 33749563 [TBL] [Abstract][Full Text] [Related]
35. Potential targets for the development of new antifungal drugs. Su H; Han L; Huang X J Antibiot (Tokyo); 2018 Nov; 71(12):978-991. PubMed ID: 30242283 [TBL] [Abstract][Full Text] [Related]
36. Management of mycoses in surgical patients -- review of the literature. Holzheimer RG; Dralle H Eur J Med Res; 2002 May; 7(5):200-26. PubMed ID: 12069912 [TBL] [Abstract][Full Text] [Related]
37. Current drug therapy of systemic mycoses: a review. Yonga G East Afr Med J; 1995 Jun; 72(6):394-8. PubMed ID: 7498014 [TBL] [Abstract][Full Text] [Related]